Treatments directed against EGFR, such as anti-VEGF monoclonal antibodies (bevacizumab) and anti-EGFR cetuximab or panitumumab, improve clinical outcomes in terms of overall survival and disease-free survival when combined with first-line chemotherapy treatments for metastatic colon cancer. Aims. To determine the epidemiological, clinical, and survival-related variables associated with the treatment of KRAS wild-type metastatic colon cancer with anti-EGFR agents in our institution. Patients & methods. We performed a retrospective review of the electronic files of patients with KRAS wild-type metastatic colon cancer treated with cetuximab between 2014 and 2019. Results. 169 patients diagnosed with metastatic Colorectal Cancer RAS WT receiving anti-EGFR treatment. The median age was 65 years, with 54% male. 91% with ECOG 0 – 1. KRAS test was performed to 100% of patients. 70% had a tumor on the left side of the colon. Objective response was 4.8%. The median PFS was 3 months and median OS was 5 months. Only the use of combined schemes such as FOLFIRI with cetuximab and exposure to cetuximab in some lines of treatment were shown to be significant prognostic factors for PFS, compared with those who did not receive it. Rash G1-2 was the most common adverse event. Conclusions. the epidemiological and clinical characteristics of our patients are like the world literature, however, the PFS and OS reached are lower than expected as well as adverse events registered. Most of the patients received anti-EGFR treatment in second line. These results allowed us to propose anti-EGFR treatment in colorectal cancer from the front line at the National Oncology Institute.
| Published in | International Journal of Clinical Oncology and Cancer Research (Volume 7, Issue 2) |
| DOI | 10.11648/j.ijcocr.20220702.14 |
| Page(s) | 35-40 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Colorectal Cancer, Metastatic, KRAS Wild-Type, Anti-EGFR, Progression-Free Survival, Overall Survival
| [1] | Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 394 (10207), 1467–1480 (2019). |
| [2] | REGISTRO HOSPITALARIO DE CÁNCER RHC-ION. Boletín 2019. |
| [3] | Del RN, Panam NDE. República de Panamá Ministerio de Salud Dirección de Planificación de Salud Departamento de Registros y Estadísticas de Salud REGISTRO NACIONAL DEL CÁNCER BOLETÍN ESTADÍSTICO. 2014-6, (2012). |
| [4] | Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J. Exp. Clin. Cancer. Res. 37 (1), 57 (2018). This review highlights the emerging experimental strategies for blocking KRAS function and signaling its direct targeting. |
| [5] | Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther. 5 (1), 22 (2020). The authors provide an overview of existing CRC-targeted agents and their underlying mechanisms, as well as a discussion of their limitations and future trends. |
| [6] | Li QH, Wang YZ, Tu J et al. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol. Rep. (Oxf). 8 (3), 179–191 (2020). |
| [7] | Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 (4), 337–345 (2004). |
| [8] | Van Cutsem E, Köhne C-H, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360 (14), 1408–1417 (2009). |
| [9] | Douillard JY, Siena S, Cassidy J et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann. Oncol. 25 (7), 1346–1355 (2014). |
| [10] | Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (14), 2311–2319 (2008). Cetuximab and irinotecan improved progression-free survival and response rate and led to better quality of life than irinotecan alone. |
| [11] | Passardi A, Scarpi E, Gelsomino F et al. Impact of second line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: Results from the ITACa randomized clinical trial. Sci. Rep. 7 (1), 10246 (2017). Results from the ITACa trial showed that, in patients with wild-type KRAS metastatic colorectal cancer, addition of cetuximab to second-line chemotherapy increased PFS. |
| [12] | Scope A, Agero ALC, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J. Clin. Oncol. 25 (34), 5390–5396 (2007). |
| [13] | Bouché O, Ben Abdelghani M, Labourey J-L et al. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J. Gastroenterol. 25 (29), 4007–4018 (2019). |
| [14] | Petrelli F, Ardito R, Ghidini A et al. Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis. Oncology. 94 (4), 191–199 (2018). |
| [15] | Chen K-H, Shao Y-Y, Chen H-M et al. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study. BMC Cancer. 16, 327 (2016). Left-sided primary tumor site is a useful predictor of improved efficacy of cetuximab in third-line or salvage treatment of KRAS wild-type metastatic colorectal cancer. |
| [16] | Siegel RL, Miller KD, Goding Sauer A et al. Colorectal cancer statistics, 2020 CA. Cancer J. Clin. 70 (3), 145–164 (2020). |
| [17] | Iwamoto S, Hazama S, Kato T et al. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res. 34 (4), 1967–1973 (2014). |
| [18] | Yang YF, Wang GY, He JL, Wu FP, Zhang YN. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore). 96 (12), e6335 (2017). |
| [19] | Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol. 20 (15), 4208–4219 (2014). Adding cetuximab to standard chemotherapy increases the response rate in patients with wild-type KRAS and can thus increase the resectability rate for liver metastases. |
| [20] | Aljehani MA, Morgan JW, Guthrie LA et al. Association of primary tumor site with mortality in patients receiving bevacizumab and cetuximab for metastatic colorectal cancer. JAMA Surg. 153 (1), 60–67 (2018). |
| [21] | Liu Y, Wang F, Ma N et al. Continued cetuximab in second-line treatment for patients with unresectable metastatic wild-type KRAS, NRAS, and BRAF colorectal cancer after disease progression during first-line cetuximab-based therapy. J. Clin. Oncol. Abstract 127 (2020). |
APA Style
Kayra Sánchez-Muñoz, José Pinto-Llerena. (2022). Anti-EGFR–Based Treatment of Patients with Metastatic Colorectal Cancer: Data from the National Oncology Institute of Panama. International Journal of Clinical Oncology and Cancer Research, 7(2), 35-40. https://doi.org/10.11648/j.ijcocr.20220702.14
ACS Style
Kayra Sánchez-Muñoz; José Pinto-Llerena. Anti-EGFR–Based Treatment of Patients with Metastatic Colorectal Cancer: Data from the National Oncology Institute of Panama. Int. J. Clin. Oncol. Cancer Res. 2022, 7(2), 35-40. doi: 10.11648/j.ijcocr.20220702.14
AMA Style
Kayra Sánchez-Muñoz, José Pinto-Llerena. Anti-EGFR–Based Treatment of Patients with Metastatic Colorectal Cancer: Data from the National Oncology Institute of Panama. Int J Clin Oncol Cancer Res. 2022;7(2):35-40. doi: 10.11648/j.ijcocr.20220702.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcocr.20220702.14,
author = {Kayra Sánchez-Muñoz and José Pinto-Llerena},
title = {Anti-EGFR–Based Treatment of Patients with Metastatic Colorectal Cancer: Data from the National Oncology Institute of Panama},
journal = {International Journal of Clinical Oncology and Cancer Research},
volume = {7},
number = {2},
pages = {35-40},
doi = {10.11648/j.ijcocr.20220702.14},
url = {https://doi.org/10.11648/j.ijcocr.20220702.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20220702.14},
abstract = {Treatments directed against EGFR, such as anti-VEGF monoclonal antibodies (bevacizumab) and anti-EGFR cetuximab or panitumumab, improve clinical outcomes in terms of overall survival and disease-free survival when combined with first-line chemotherapy treatments for metastatic colon cancer. Aims. To determine the epidemiological, clinical, and survival-related variables associated with the treatment of KRAS wild-type metastatic colon cancer with anti-EGFR agents in our institution. Patients & methods. We performed a retrospective review of the electronic files of patients with KRAS wild-type metastatic colon cancer treated with cetuximab between 2014 and 2019. Results. 169 patients diagnosed with metastatic Colorectal Cancer RAS WT receiving anti-EGFR treatment. The median age was 65 years, with 54% male. 91% with ECOG 0 – 1. KRAS test was performed to 100% of patients. 70% had a tumor on the left side of the colon. Objective response was 4.8%. The median PFS was 3 months and median OS was 5 months. Only the use of combined schemes such as FOLFIRI with cetuximab and exposure to cetuximab in some lines of treatment were shown to be significant prognostic factors for PFS, compared with those who did not receive it. Rash G1-2 was the most common adverse event. Conclusions. the epidemiological and clinical characteristics of our patients are like the world literature, however, the PFS and OS reached are lower than expected as well as adverse events registered. Most of the patients received anti-EGFR treatment in second line. These results allowed us to propose anti-EGFR treatment in colorectal cancer from the front line at the National Oncology Institute.},
year = {2022}
}
TY - JOUR T1 - Anti-EGFR–Based Treatment of Patients with Metastatic Colorectal Cancer: Data from the National Oncology Institute of Panama AU - Kayra Sánchez-Muñoz AU - José Pinto-Llerena Y1 - 2022/05/12 PY - 2022 N1 - https://doi.org/10.11648/j.ijcocr.20220702.14 DO - 10.11648/j.ijcocr.20220702.14 T2 - International Journal of Clinical Oncology and Cancer Research JF - International Journal of Clinical Oncology and Cancer Research JO - International Journal of Clinical Oncology and Cancer Research SP - 35 EP - 40 PB - Science Publishing Group SN - 2578-9511 UR - https://doi.org/10.11648/j.ijcocr.20220702.14 AB - Treatments directed against EGFR, such as anti-VEGF monoclonal antibodies (bevacizumab) and anti-EGFR cetuximab or panitumumab, improve clinical outcomes in terms of overall survival and disease-free survival when combined with first-line chemotherapy treatments for metastatic colon cancer. Aims. To determine the epidemiological, clinical, and survival-related variables associated with the treatment of KRAS wild-type metastatic colon cancer with anti-EGFR agents in our institution. Patients & methods. We performed a retrospective review of the electronic files of patients with KRAS wild-type metastatic colon cancer treated with cetuximab between 2014 and 2019. Results. 169 patients diagnosed with metastatic Colorectal Cancer RAS WT receiving anti-EGFR treatment. The median age was 65 years, with 54% male. 91% with ECOG 0 – 1. KRAS test was performed to 100% of patients. 70% had a tumor on the left side of the colon. Objective response was 4.8%. The median PFS was 3 months and median OS was 5 months. Only the use of combined schemes such as FOLFIRI with cetuximab and exposure to cetuximab in some lines of treatment were shown to be significant prognostic factors for PFS, compared with those who did not receive it. Rash G1-2 was the most common adverse event. Conclusions. the epidemiological and clinical characteristics of our patients are like the world literature, however, the PFS and OS reached are lower than expected as well as adverse events registered. Most of the patients received anti-EGFR treatment in second line. These results allowed us to propose anti-EGFR treatment in colorectal cancer from the front line at the National Oncology Institute. VL - 7 IS - 2 ER -
Information
Email: